Activation of cultured vascular endothelial cells by antiphospholipid antibodies. - Wikidata - awgldk - TriplyDB

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

http://www.wikidata.org/entity/Q33488617

about

High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318 Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies.Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome.Beta2 glycoprotein I containing immune-complexes in lupus patients: association with thrombocytopenia and lipoprotein (a) levels.A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies.Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome.Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells.Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease.Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies.Antiphospholipid antibodies: paradigm in transition.The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.Microangiopathic antiphospholipid antibody-associated syndrome in a pregnant lady.beta 2-Glycoprotein I: target antigen for autoantibodies in the 'antiphospholipid syndrome'.Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.Complement system on the attack in autoimmunity Antibodies to serine proteases in the antiphospholipid syndrome.Apoptosis in human autoimmune diseases.The endothelium in atherogenesis.Accelerated atheroma and anti-beta2-glycoprotein I antibodies.Autoimmunity in atherosclerosis: lessons from experimental models.Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII).Placentation, antiphospholipid syndrome and pregnancy outcome.Atherosclerosis and autoimmunity.Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage.The role of tissue factor in the antiphospholipid syndrome.Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors Antiphospholipid syndrome: an overview.Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells.Cerebral haemostasis and antiphospholipid antibodies.Antiphospholipid Syndrome during pregnancy: the state of the art

P2860

Q22254095-3421304D-678F-4AD7-AA08-A573B4881FDF Q24561680-13EADEEF-0DCE-4C37-91E4-983558AFE569 Q28260452-F8A1298B-60D6-4D35-A727-D231C36B3B3D Q28291393-6FF51232-F09F-4E0A-814B-E3B0DC5481DA Q28344929-57E0C1C4-9DDD-41D0-8F53-1C56E4901606 Q30422807-67FDDB86-0C50-4DBB-8E85-26E58E4BE4DF Q30676844-E63B6D44-5F5B-48FD-AD5D-92FD2CD61F17 Q30896030-8E358491-9AA5-4A89-8F88-D8AE68161196 Q33328443-A7AB2511-4BCD-45F0-A429-A1EADA38C21C Q33330540-4AEDD6AA-522A-41AF-8FDD-33E6D48746C5 Q33332894-BCDAA1B8-772C-4124-9473-78FBE72A692C Q33335746-3BFA8DD1-0E8F-493A-9A0C-B27F80684683 Q33335807-4D69A1F5-D3B2-46C4-9D18-216ECDE4B323 Q33340713-A1757A71-4EFA-455B-BBDB-90454071AAA3 Q33360771-FCF696D6-0F82-4CC9-A7B3-98DFE60A5A41 Q33382848-1233726C-5693-4D2D-8825-E16CF1690681 Q33431097-02053B2F-2AD2-453E-BB31-E6D900FDBDC9 Q33435712-3F3CC03F-94CB-45DE-8CF8-6611BA64123B Q33497587-AFEE7681-ACB8-4A12-92E9-09C9BC035A9B Q33502380-304FF1AE-70F7-4D3A-9ACE-9A1EC60F1CC2 Q33630007-3C915BD4-42F7-4701-B458-315DF59445C7 Q33630290-5F6F76C1-E35E-436F-992F-01079CC02C05 Q33670367-44366F61-5CBF-46E3-A310-1D7AA9D3EFF1 Q33836352-5A2E0E9E-B1C1-405D-8225-A65B983A4280 Q33915443-826F19CB-B49B-45BE-97EF-24FE2452CDCB Q33915467-C916ACFA-4117-43D5-B347-BD2094394E36 Q33915478-86D45F66-9530-4791-9937-011D0B93A173 Q33948737-11890D00-522A-48E8-8917-F4EB752E8C54 Q34169570-90123834-E369-4598-9AA1-8B77F91D9E38 Q34173981-61B9AA37-58BC-4536-B30F-B35583BAD593 Q34243799-76990A01-9A27-47BF-BB8E-21948449DAFB Q34371560-B5EB8E43-EE42-492A-A94F-BB93136A47BA Q34441079-2C81EC95-1D15-4369-A64A-759B5483356B Q34749444-E3266E57-8732-4989-9E13-413E105FEDAC Q34963070-7187235F-6720-45BA-888C-3288664F345D Q35067429-B4597F94-475D-4E81-AA76-DBE19A9A4688 Q35099505-126C0C3E-6905-4B63-A393-C05C0552853F Q35189302-32F6512A-00C5-426F-B5B0-09580493342D Q35625236-3E0F4674-F1FF-414B-801D-D96B5A07163E Q35756040-AAEE5B11-A872-40FA-9B57-61DB69830A35

P2860

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

http://www.wikidata.org/entity/Q33488617

description

1995 nî lūn-bûn

@nan

1995 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

@ast

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

@en

type

label

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

@ast

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

@en

prefLabel

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

@ast

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

@en

P1433

Q33488617-2F58FC20-48C8-45A0-8974-0FA81A3D66C0

P1476

Q33488617-B0C7E399-1403-4B8B-8E88-BCF41A95449C

P2093

Q33488617-05EF4439-A30C-4546-8876-0222883C45EC

Q33488617-066F96CD-C9D8-405B-B85F-67F93575A195

Q33488617-2743690D-A42B-45A1-B6BC-A59EE7153A0E

Q33488617-2E51845B-2F1F-4C30-8305-EC6A058F556B

Q33488617-82228156-8C3D-42D2-828B-6FB98807A367

P2860

Q33488617-0A9A2E40-5D21-4969-B7D6-5F3CAFE7573A

Q33488617-0CAAF5DA-247B-4340-8D97-AFADE3513BAC

Q33488617-123C6E54-41BA-494C-9740-C1AA44ED9ADA

Q33488617-15C7B6EE-BCD6-4F24-B0AC-6542C72131A2

Q33488617-21DF2950-780E-40B3-8C95-77B896D6CEC6

Q33488617-222534EA-E6B2-4291-99BE-3DE8DD6F3B11

Q33488617-46CF33E2-8BC6-4197-BEAE-2067CCB00FD7

Q33488617-4B420ED1-1385-4B3C-B19A-5E9354D49DC6

Q33488617-4E81CF98-3FB2-4ADA-9A22-A80859DF210A

Q33488617-583F8943-5C01-4488-824F-240C4FF42D37

P304

Q33488617-CD61DC2C-D9FA-4DF0-90C0-B8F6AB667711

P31

Q33488617-BE615973-59C3-45A2-B8D0-35B1290BE223

P356

Q33488617-23FC8011-D09D-4C51-B1A1-B2CFCB9817C6

P407

Q33488617-113C69BC-BD71-4FCB-A0A8-A1E8F956A57C

P433

Q33488617-F5005126-F0B2-443F-97ED-E0886190CCA7

P478

Q33488617-8E0151B3-D617-4FB5-975C-DDE319831D7C

P50

Q33488617-88B3C870-242A-4D0C-9007-7AE8638DB0B4

Q33488617-BE4BCCAC-CE5C-4A45-A2B5-2BCB21006B1C

P577

Q33488617-AE4D14E1-AA24-46F1-B2B1-7F0EFE29DF7D

P698

Q33488617-CC8E4211-AD4B-49E5-BA0C-8450141D35A3

P921

Q33488617-0B49FCFA-26D9-4D9C-8931-2210A59797CD

Q33488617-103107DD-6F04-426F-9848-9FDE5463AF90

P932

Q33488617-4FBC90D7-9076-4DE8-AA30-BCC56867BB6D

P356

P1433

Journal of Clinical Investigation

P1476

Activation of cultured vascular endothelial cells by antiphospholipid antibodies

@en

P2093

J E Salmon

http://www.w3.org/2001/XMLSchema#string

J M LaSala

http://www.w3.org/2001/XMLSchema#string

L R Sammaritano

http://www.w3.org/2001/XMLSchema#string

R L Silverstein

http://www.w3.org/2001/XMLSchema#string

S K Lo

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein

Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions

The 1982 revised criteria for the classification of systemic lupus erythematosus

Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria

IgG anti-cardiolipin antibodies in murine lupus.

Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Antiphospholipid antibody syndrome: immunologic and clinical aspects.

Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

Anti-phospholipid antibodies.

P304

2211-2219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI118276

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Azzudin E. Gharavi

P577

1995-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7593607

http://www.w3.org/2001/XMLSchema#string

P921

P932

185871

http://www.w3.org/2001/XMLSchema#string